NEWS
Major Technological Upgrade: AIM's High-Potency Human Diploid Rabies Vaccine Approved for Clinical Trials
On March 9, AIM Vaccines announced that its independently developed high-potency human diploid rabies vaccine, which has been upgraded through iterative processes, recently received the "Approval Notice for Drug Clinical Trials" from the National Medical Products Administration. This vaccine is characterized by its exceptionally high potency.
"Animal trials show that this vaccine induces high levels of protective antibodies, with antibody levels significantly higher than those of marketed human diploid rabies control vaccines at the same dose," said an AIM official.
The announcement highlighted that compared to traditional first-generation human diploid rabies vaccines, this vaccine overcomes the technical bottlenecks of low viral titer and yield in conventional processes. Innovations in purification technology have significantly improved product quality and safety.
In terms of administration, AIM's newly developed rabies vaccine is more flexible than traditional rabies vaccines. It can be administered using the five-dose schedule, the simplified four-dose schedule, or the 2-1-1 four-dose schedule, offering greater convenience.
According to China Insights Consultancy (CIC) data, as the world's largest rabies vaccine market, China is expected to reach a scale of RMB 22 billion by 2030. Currently, AIM has completed a workshop for its high-potency human diploid rabies vaccine meeting international standards and produced Phase III clinical trial samples at commercial scale, demonstrating its capacity for large-scale production.
Recently, AIM has disclosed multiple vaccine R&D updates, including FDA approval for its mRNA RSV vaccine and domestic approval for its mRNA shingles vaccine. Additionally, its 13-valent pneumococcal conjugate vaccine has been submitted for its drug market registration application and obtained the corresponding production license, and its serum-free rabies vaccine has filed a pre-application for market registration.
Over the next 2-3 years, AIM's next-generation innovative products—including serum-free rabies vaccines, 13-valent pneumococcal conjugate vaccines, quadrivalent meningococcal conjugate vaccines, and mRNA-based RSV and shingles vaccines—are expected to launch collectively, driving AIM's leapfrog development and value revaluation.
"Animal trials show that this vaccine induces high levels of protective antibodies, with antibody levels significantly higher than those of marketed human diploid rabies control vaccines at the same dose," said an AIM official.
The announcement highlighted that compared to traditional first-generation human diploid rabies vaccines, this vaccine overcomes the technical bottlenecks of low viral titer and yield in conventional processes. Innovations in purification technology have significantly improved product quality and safety.
In terms of administration, AIM's newly developed rabies vaccine is more flexible than traditional rabies vaccines. It can be administered using the five-dose schedule, the simplified four-dose schedule, or the 2-1-1 four-dose schedule, offering greater convenience.
According to China Insights Consultancy (CIC) data, as the world's largest rabies vaccine market, China is expected to reach a scale of RMB 22 billion by 2030. Currently, AIM has completed a workshop for its high-potency human diploid rabies vaccine meeting international standards and produced Phase III clinical trial samples at commercial scale, demonstrating its capacity for large-scale production.
Recently, AIM has disclosed multiple vaccine R&D updates, including FDA approval for its mRNA RSV vaccine and domestic approval for its mRNA shingles vaccine. Additionally, its 13-valent pneumococcal conjugate vaccine has been submitted for its drug market registration application and obtained the corresponding production license, and its serum-free rabies vaccine has filed a pre-application for market registration.
Over the next 2-3 years, AIM's next-generation innovative products—including serum-free rabies vaccines, 13-valent pneumococcal conjugate vaccines, quadrivalent meningococcal conjugate vaccines, and mRNA-based RSV and shingles vaccines—are expected to launch collectively, driving AIM's leapfrog development and value revaluation.
